December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
97 citations
,
April 2016 in “Andrology” Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
1 citations
,
December 2018 in “Journal of Cosmetic Dermatology” Men with thinner hair from genetic hair loss may be more likely to have an enlarged prostate.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
January 2014 in “Shiyong laonian yixue” Tamsulosin and finasteride improve heart function and circadian rhythm in elderly men with heart failure and prostate issues.
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
11 citations
,
January 1995 in “Biomedicine & pharmacotherapy” TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
20 citations
,
December 2015 in “Der Urologe” Combining medications is more effective for treating benign prostatic syndrome symptoms.
4 citations
,
September 2006 in “European Urology Supplements” Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
December 2024 in “Zanco Journal of Medical Sciences” Finasteride and dutasteride are equally effective and safe for treating BPH.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
1 citations
,
January 2010 in “INTAS POLIVET” Two German shepherds with acute prostatitis were successfully treated with medication.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
65 citations
,
March 1999 in “Urology” Finasteride didn't significantly improve ICPPS symptoms, more research needed.
27 citations
,
August 1999 in “Urology” Finasteride improves urinary function in men for 2 years.
20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
1 citations
,
May 2017 in “Urologe A” Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.
Combined finasteride and anastrozole therapy effectively treats BPH, influenced by hormone imbalances and genetics.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
January 2012 in “Земский врач” Finasteride helps improve treatment for benign prostatic hyperplasia.
January 2012 in “Курский научно-практический вестник "Человек и его здоровье"” 5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
January 2008 in “Journal of Beijing Normal University” Terazosin hydrochloride helps with BPH and blood pressure, but not more than the control.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.
January 2014 in “Hebei yixue” Combining tamsulosin and finasteride effectively improves urinary symptoms in elderly BPH patients.
April 2026 in “The Open Biotechnology Journal” Resveratrol shows health benefits but faces challenges in effectiveness and regulation.
3 citations
,
December 2014 in “Journal of Clinical Oncology” Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
6 citations
,
January 2016 in “Evidence-based complementary and alternative medicine” Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.